Cargando…

Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases

The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is de...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, David G, Orkin, Stuart H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808730/
https://www.ncbi.nlm.nih.gov/pubmed/20017892
http://dx.doi.org/10.1186/gm114
_version_ 1782176530246402048
author Nathan, David G
Orkin, Stuart H
author_facet Nathan, David G
Orkin, Stuart H
author_sort Nathan, David G
collection PubMed
description The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions.
format Text
id pubmed-2808730
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28087302010-12-09 Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases Nathan, David G Orkin, Stuart H Genome Med Musings The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions. BioMed Central 2009-12-09 /pmc/articles/PMC2808730/ /pubmed/20017892 http://dx.doi.org/10.1186/gm114 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Musings
Nathan, David G
Orkin, Stuart H
Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title_full Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title_fullStr Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title_full_unstemmed Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title_short Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
title_sort musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
topic Musings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808730/
https://www.ncbi.nlm.nih.gov/pubmed/20017892
http://dx.doi.org/10.1186/gm114
work_keys_str_mv AT nathandavidg musingsongenomemedicineenzymereplacementtherapyofthelysosomalstoragediseases
AT orkinstuarth musingsongenomemedicineenzymereplacementtherapyofthelysosomalstoragediseases